GlaxoSmithKline (GSK) Rating Reiterated by UBS Group

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reissued by analysts at UBS Group in a research note issued to investors on Friday, Borsen Zeitung reports. They presently have a GBX 1,630 ($21.30) price objective on the stock. UBS Group’s price objective indicates a potential upside of 4.63% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Barclays reissued an “equal weight” rating on shares of GlaxoSmithKline in a research note on Wednesday, April 10th. Credit Suisse Group set a GBX 1,600 ($20.91) price target on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Wednesday, April 10th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, May 2nd. Bryan, Garnier & Co dropped their price target on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a “neutral” rating on the stock in a research note on Thursday, May 2nd. Finally, HSBC reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Tuesday, May 14th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of GBX 1,526.14 ($19.94).

Shares of GSK opened at GBX 1,557.80 ($20.36) on Friday. GlaxoSmithKline has a 52-week low of GBX 1,408.80 ($18.41) and a 52-week high of GBX 1,648.80 ($21.54). The company has a current ratio of 0.72, a quick ratio of 0.45 and a debt-to-equity ratio of 942.07. The company has a market capitalization of $76.89 billion and a price-to-earnings ratio of 19.84.

In other news, insider Manvinder Singh Banga bought 458 shares of the stock in a transaction dated Wednesday, May 1st. The shares were bought at an average cost of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Story: Stock Selection – What is cash flow?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.